Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations?

The Pediatric Infectious Disease Journal
Ashley StarkRachel G Greenberg

Abstract

We sought to compare meropenem and fluconazole dosing in the neonatal intensive care unit with recommendations based on published pharmacokinetic (PK) studies in infants. We performed an observational cohort study of infants <90 days postnatal age who received a course of meropenem or fluconazole who were treated in neonatal intensive care units managed by the Pediatrix Medical Group (1997-2016). We defined any dose amount from 80% to 120% of the published recommendation to constitute an appropriate dose of either antimicrobial. We calculated the percentage of appropriately dosed courses overall and by discharge year. We then evaluated the change in appropriate dosing over time using a nonparametric test of trend to evaluate the proportion of appropriately dosed courses of each antimicrobial by discharge year. A total of 3608 infants were administered 2025 courses of meropenem and 1201 courses of fluconazole. Of all meropenem courses, 32% were dosed appropriately (increased significantly over time; P = 0.01), while 17% of fluconazole courses were dosed appropriately (increased significantly over time; P = 0.01). Median dosing for both meropenem and fluconazole was at or below recommendations; therefore, under-dosing was more co...Continue Reading

References

Jan 1, 1985·Statistics in Medicine·J Cuzick
Feb 11, 2005·Seminars in Fetal & Neonatal Medicine·Sharon Conroy, John McIntyre
Jul 23, 2008·The Pediatric Infectious Disease Journal·John S BradleyEdmund V Capparelli
Jul 14, 2009·The Pediatric Infectious Disease Journal·Kelly C WadeJeffrey S Barrett
Sep 29, 2009·Pharmacoepidemiology and Drug Safety·Ching-Lan ChengYuh-Jyh Lin
Nov 19, 2010·The Pediatric Infectious Disease Journal·Lauren PiperDaniel K Benjamin
Aug 11, 2011·The Pediatric Infectious Disease Journal·P Brian SmithUNKNOWN Meropenem Study Team
Aug 11, 2012·Current Medicinal Chemistry·K TurnerM M Laughon
Dec 19, 2013·American Journal of Perinatology·Emily M HsiehUNKNOWN Best Pharmaceuticals for Children Act—Pediatric Trials Network
Oct 1, 2014·Pediatric Research·Lawrence C Ku, P Brian Smith
Aug 11, 2015·British Journal of Clinical Pharmacology·Kate O'HaraJennifer H Martin
Jan 23, 2016·BMC Pediatrics·Alcidésio Sales de SouzaHelena Lutéscia Luna Coelho
May 5, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Raffaele CoppiniKarel Allegaert
Jul 31, 2016·Clinical Therapeutics·Jacob K Johnson, Matthew M Laughon
Jan 18, 2018·International Journal of Clinical Pharmacy·T B Y LiemC M A Rademaker
Apr 7, 2018·British Journal of Clinical Pharmacology·Robert B FlintUNKNOWN DINO Research group
Apr 24, 2018·The Journal of Antimicrobial Chemotherapy·Eva GermovsekUNKNOWN NeoMero Consortium

❮ Previous
Next ❯

Citations

Jun 30, 2021·Journal of Clinical Pharmacology·Jian WangGilbert J Burckart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

Enfermedades infecciosas y microbiología clínica
Revista de medicina de la Universidad de Navarra
M Escolar, J Honorato
Antibiotiki i khimioterapii︠a︡ = Antibiotics and chemoterapy [sic]
S M Shatunov, Iu B Belousov
The Pediatric Infectious Disease Journal
J S Bradley
© 2021 Meta ULC. All rights reserved